A r t i c l e s
Naive T cells are stimulated to differentiate into specialized effector cells mainly through the actions of secreted cytokines. Helper T cells have been typically considered to fall into one of two effector cell lineages; T helper type 1 (T H 1) and T H 2 cells modulate cellular and humoral T cell immunity, respectively, on the basis of their cytokine expression profiles 1 . Subsequent work has described 'T H -17' cells, a third lineage of effector helper T cells distinct from and in fact antagonized by products of the T H 1 and T H 2 lineages 2, 3 . Named for its 'signature' cytokine, interleukin , this third subset of helper T cells seems to have evolved as an arm of the adaptive immune system specialized for enhanced host protection against extracellular bacteria and some fungi, as these microbes may not be effectively controlled by T H 1 or T H 2 responses 4, 5 . The varied tissue sources of cytokines that induce the differentiation and regulate the homeostasis of T H -17 cells (IL-23, IL-6 and transforming growth factor-β), together with the presence of IL-17 receptors on both hematopoietic and nonhematopoietic cells, emphasize the complicated relationships that exist between cells of the adaptive and innate immune systems. Although the full scope of T H -17 cell effector functions is still emerging, the strong inflammatory response promoted by T H -17 cells has been associated with the pathogenesis of several autoimmune and inflammatory disorders previously attributed to T H 1 or T H 2 cells, including rheumatoid arthritis, multiple sclerosis and psoriasis 4 . Thus, targeting T H -17 cells for the treatment of autoimmune and inflammatory disorders, either directly through IL-17 blockade or indirectly through inhibition of IL-23, is now being pursued clinically. However, the structural uniqueness of the IL-17 system, combined with a dearth of biochemical and structural information on receptor interactions, remains a barrier to the development of mechanism-or structure-based antagonists.
The IL-17 family is composed of six cytokines and five receptors, and the ligand-receptor pairing is not completely worked out for all members 6 . On the basis of the crystal structure of IL-17F, the six structurally related IL-17 cytokines (IL-17A through IL-17F) are predicted to form a homodimeric fold (or heterodimeric fold in the case of IL-17A-IL-17F) homologous to that of the cysteine-knot growth factors such as nerve growth factor (NGF) 7, 8 . T H -17 cell-derived IL-17A and IL-17F share the greatest homology in the family (50%) and require both IL-17 receptor A (IL-17RA; A001253) and IL-17RC for signaling 9, 10 . Although it has been shown that fibroblasts, epithelial and endothelial cells coexpress both IL-17RA and IL-17RC, T cells do not express IL-17RC and express only IL-17RA 11 . It was thought that lymphocytes are not responsive to IL-17; however, it has now been reported that T cells can indeed respond directly to .
The five IL-17 receptors (IL-17RA through IL-17RE) are not homologous to any known receptors and show considerable sequence divergence. All seem to contain extracellular domains composed of fibronectin type III (FnIII) domains and cytoplasmic SEF-IL-17R domains that show loose homology to Toll-IL-1R domains 13, 14 . The IL-17 receptors mediate signaling events that are distinct from those triggered by the more widely known receptors for type I four-helix cytokines 15, 16 . Like stimulation of the Toll-like receptor, stimulation of the IL-17 receptor results in activation of the transcription factor NF-κB and mitogen-activated protein kinases. However, IL-17 receptor signaling does not use the same set of membrane-proximal adaptor molecules as Toll-like receptor signaling does; IL-17R requires the adaptor Act1, which also contains a SEF-IL-17R domain [17] [18] [19] . These unique signaling properties of IL-17 receptors enable T H -17 cells to act as a bridge between cells of the innate and adaptive immune systems. Mechanistically, fluorescence resonance energy transfer studies have A r t i c l e s suggested that IL-17RA may exist as a preformed dimer on the cell surface that undergoes a conformational change after binding IL-17 to form a heterodimeric signaling complex with IL-17RC. However, the molecular basis for how a homodimeric IL-17 cytokine would pair with two different receptors has remained unknown 14, 20 .
RESULTS

Structure of IL-17RA bound to IL-17F
We determined the crystal structure of IL-17RA bound to IL-17F at a resolution of 3.3 Å by single isomorphous replacement with anomalous scattering phasing ( Table 1) . We expressed IL-17F from baculovirus and expressed the IL-17RA extracellular domain with human embryonic kidney 293S cells deficient in acetylglucosaminyltransferase I (293S GnTI-cells). To facilitate crystallization, we methylated the complex and 'shaved' the heavily glycosylated receptor extracellular domain with endoglycosidase H before crystallization to improve homogeneity (described in Online Methods) which left one N-acetylglucosamine residue at each of the asparagine-linked glycosylation sites (Fig. 1) . Biochemically, the 'shaved' and 'unshaved' complexes behaved identically (data not shown). By gel filtration, mixtures of IL-17F or IL-17A with extracellular domain of IL-17RA resulted in coelution of complexes with a stoichiometry of 2:2 (two receptors plus one IL-17 dimer) or 1:2 (one receptor plus one IL-17 dimer), with the main species having a stoichiometry of 1:2. We detected the complex with a stoichiometry of 2:2 only at high protein concentrations, whereas at lower concentrations, the complex with a stoichiometry of 1:2 predominated even in the presence of excess IL-17RA. The crystals contained one IL-17RA bound to one IL-17F homodimer (Fig. 1) . As discussed below, this 'partial' signaling complex may in fact be the biologically relevant form of the IL-17RA-IL-17F and IL-17RA-IL-17A complexes.
The IL-17RA ectodomain is composed of two unusual FnIII domain modules joined by an 18-amino acid linker ( Fig.1  and Supplementary Fig. 1 ). Although it is not apparent from the sequence, the IL-17RA structure is reminiscent of that of hematopoietic cytokine receptors in that it contains tandem β-sandwich domains; however, the domains themselves have some substantial deviations from canonical FnIII folds, and the manner of ligand interaction is entirely distinct from that of other cytokine receptors. We modeled residues 2-272 of the predicted 286 ectodomain residues (where residue 1 is the first amino acid of the mature peptide) into continuous electron density for the receptor chain and clearly visualized five of the potential seven N-linked glycans (electrondensity map quality, Supplementary  Fig. 2 ). The first FnIII domain (D1) has an additional 40-amino acid aminoterminal extension that forms a unique fold (Supplementary Fig. 1) . The chain makes a hairpin-like turn bridged by a disulfide bond (Cys12-Cys19), and the second strand of the turn forms a β-strand (A′) that extends the FnIII β-sheet and then wraps around the face of D1, forming disulfide bonds with Cys95 of the C′ strand before passing over the domain to start the A strand of the FnIII domain. The interdomain linker region contains a short helix and is stabilized by an internal disulfide bond (Cys154-Cys165). The second FnIII domain (D2) has two atypical disulfide bonds, one linking the C-C′ loop (Cys214) to the D-F loop (Cys245) and a second in the F-G loop (Cys259-Cys263). We predict that a third disulfide bond exists between the F-G loop (Cys246) and the carboxyl terminus of the G strand (Cys272), similar to that observed in class II cytokine receptors 21 ; however, this bond is not well defined in the present electron density map.
Although the core structure of the IL-17RA-bound IL-17F molecule was essentially unchanged compared with that of the form of IL-17F not receptor bound 7 , peripheral strands and loops underwent structural accommodations to facilitate binding to IL-17RA. The conformation observed in the IL-17F structure that was not receptor bound could not be maintained in the IL-17RA-bound state, as it would generate steric clashes with the amino-terminal coil region of the receptor. Each IL-17F monomer is composed of two pairs of antiparallel β-sheets (strands 1-4), with the second and fourth strands connected by two disulfide bonds in a manner homologous to that of proteins of the cysteine-knot family. There is a 50-amino acid amino-terminal extension of which residues 29-42 are parallel to strands 3 and 4 of the second IL-17F protomer. This coil region is stabilized by many interactions, including several hydrogen bonds with the adjacent strands. In the IL-17RA-bound IL-17F conformation, this region (residues [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] moves out to open the binding pocket and interact with the receptor (Fig. 2a) . The first 24 amino acids of each IL-17F chain and residues 105-109 from the 3-4 loop on one IL-17F protomer could not be modeled. In the IL-17F structure that is not receptor bound, Cys17 forms a disulfide 
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bond with Cys107 at the tip of the 3-4 loop on the adjacent IL-17F chain. These interchain disulfide bonds were not modeled but were present, as our protein acted like a disulfide-linked dimer by SDS-PAGE (data not shown).
IL-17RA-IL-17F binding interface
The overall mode for the binding of IL-17F to IL-17RA, in which both receptor FnIII domains bind in a 'side-on' orientation and use edge strands to insert into a crevasse formed at the dimeric interface of the ligand, is unlike that of other cytokine or growth factor receptor complexes. IL-17RA forms an extensive binding interface with IL-17F, burying ~2,200 Å 2 of surface area; ~70% of this buried surface area is mediated by the IL-17RA D1 domain. There are three main interaction sites at the binding interface (Fig. 2) . Site 1 is formed between the amino-terminal extension of IL-17RA (Thr25-Trp31) and the 1-2 loop (Pro60-Tyr63) plus the carboxyterminal region of strand 3 (Val100 and Arg102) of IL-17F chain B; this interaction buries ~330 Å 2 ( Fig. 2c) . Trp31 of the receptor is buried in the center of this binding site; the main-chain oxygen atom forms hydrogen bonds with Arg102 and the side chain forms hydrogen bonds with Pro60. Two additional hydrogen bonds are formed between Thr25 and Cys26 of IL-17RA and Tyr63 of IL-17F. Site 2 is the most prominent interface feature of the complex and is composed of the C′-C loop of IL-17RA D1 (Leu86-Arg93), which slots into a deep binding pocket flanked by the amino-terminal extension and strand 2 of IL-17F chain B and strand 3 of IL-17F chain A; this interaction buries almost 550 Å 2 ( Fig. 2a,b) . This eight-amino acid IL-17RA loop forms extensive hydrophobic and polar interactions with both chains of IL-17F, including a potential salt bridge between Glu92 of IL-17RA and Arg37 of IL-17F chain B, and a hydrogen bond between the main-chain oxygen atom of Asn89 of IL-17RA and Asn95of IL-17F chain A. Site 3, which encompasses ~410 Å 2 of buried surface area, is formed between the F-G loop of IL-17RA D2 (Cys259-Arg265) and the carboxy-terminal regions of strands 3 and 4 of IL-17F chain A, and the amino-terminal extension of IL-17F chain B (Fig. 2d) . Site 3 is rich in charged interactions, with nine potential hydrogen bonds and a salt bridge between Asp262 of IL-17RA and Arg47 of IL-17F chain B. Overall the interface is extensive and is composed of many specific contacts. We envisage that an analogous binding mode is used by other IL-17 receptor-cytokine pairs, given the sequence conservation of contact residues (discussed below).
Heterodimeric receptor complex formation
The stoichiometries of the receptor complexes remain to be fully elucidated 6 , but the asymmetric IL-17RA-IL-17F complex hints at a 'preference' for the formation of heterodimers with a second, A r t i c l e s different receptor. We therefore investigated the mechanism by which a homodimeric cytokine could possibly coordinate two different receptors. IL-17RA and IL-17RC can each bind independently to IL-17A and IL-17F, but both receptors are necessary for signaling 9, 10, 22 . To further understand how the signaling complex is formed, we devised a surface plasmon resonance (SPR) strategy using soluble proteins to measure the affinities of both the homodimeric and heteromeric receptor complexes for cytokines in vitro. Although the binding affinities of IL-17RA and IL-17RC for IL-17A and IL-17F have been reported 7, 22 , we considered it pertinent to assess the binding affinity of the second receptor-binding site. Our strategy was to immobilize one receptor on the SPR chip at a low coupling density to minimize possible formation of homodimers (that is, cross-linking) of the receptors on the chip. The dimeric IL-17 cytokine was then captured by this receptor so that each receptor would be bound to one dimeric IL-17 ligand, leaving an exposed and accessible second receptor-binding site. We subsequently passed the second receptor over the preformed receptor-cytokine complexes to measure the affinity of the second receptor-binding event. In this way, we assembled the complex in a stepwise manner and measured each of the binding affinities (Fig. 3) . IL-17A bound to both IL-17RA and IL-17RC with high affinity (2.8 ± 0.9 nM and 1.2 ± 0.1 nM, respectively). After IL-17A was bound by one IL-17RA molecule, the binding affinity for a second IL-17RA was diminished to 3.1 ± 0.5 µM, whereas the affinity of IL-17RC for this second binding site was 174 ± 3 nM. When IL-17A was originally captured by IL-17RC, a second IL-17RA bound to the existing IL-17RC-IL-17A complex with an affinity of 162 ± 29 nM; the binding affinity of a second IL-17RC to an existing IL-17RC-IL-17A complex was only 8.0 ± 0.5 µM.
We observed a similar pattern for IL-17F, which has a higher affinity for IL-17RC (4.4 ± 0.2 nM) than for IL-17RA (292 ± 19 nM). Given the divergent affinities, it seemed likely that IL-17F would be initially captured by IL-17RC; once bound, the affinity of IL-17RA for the IL-17RC-IL-17F complex was 23.8 ± 3 µM. In contrast, the binding affinity of IL-17RA and IL-17RC for preformed IL-17RA-IL-17F and IL-17RC-IL-17F complexes, respectively, was so weak that it could not be calculated accurately over the concentration range used for these experiments. Thus, these findings show that engagement of IL-17RA or IL-17RC by IL-17A or IL-17F encourages a 'preference' for the second receptor-binding site to engage a different receptor and thereby to form a heterodimeric receptor complex.
IL-17RA has been linked to signaling by IL-17E (also known as IL-25) together with IL-17RB 23 . IL-25 promotes T H 2 inflammatory responses and shares approximately 20% identity with IL-17A and IL-17F. Binding experiments have demonstrated that although IL-25 binds to IL-17RB with high affinity, it has no apparent affinity for IL-17RA [23] [24] [25] . We hypothesized that IL-17RA may bind IL-25 only after IL-25 is captured by IL-17RB. To test our hypothesis, we immobilized IL-17RB on an SPR chip, captured IL-25 and measured the affinity of IL-17RA for the IL-17RB-IL-25 complex. In support of our hypothesis, IL-17RA bound to the IL-17RB-IL-25 complex with an affinity of 14.1 ± 2.4 µM (Fig. 3) . At concentrations up to 50 µM, we found no interaction between IL-17RA and IL-25 or between the IL-17RB-IL-25 
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A r t i c l e s complex and a second IL-17RB molecule. Together with the IL-17A and IL-17F binding data, these results indicate that formation of the heteromeric complex may be mediated by allostery and/or an interaction between the receptors.
To further address that idea, we modeled a second IL-17RA molecule to form the hypothetical receptor-cytokine complex with a stoichiometry of 2:2 (Fig. 3b) . Assuming that the second receptor binds in a way identical to the binding of the first receptor, the base of one IL-17RA D2 would come into very close proximity with D2 of the second IL-17RA (Fig. 3b) . For two IL-17RA molecules bound to IL-17F, His212 on the C-C′ loop of one IL-17RA would potentially clash with His212 of the second IL-17RA (Supplementary Fig. 3 ). This potential interaction site may allow the receptors to regulate their pairing. Steric clashes may cause lower affinity for a second identical receptor, or favorable receptorreceptor interactions may stabilize heteromeric receptor complexes. We cannot rule out the possibility that homodimeric receptor complexes could form on cells in certain conditions; however, our data indicate that receptor heterodimers are probably the main signaling species (discussed below).
IL-17RA as a common receptor
IL-17RA binds to IL-17A with an affinity ~100-fold higher than its affinity for IL-17F. IL-17A and IL-17F share ~50% identity, and mapping the conserved residues onto the structure of IL-17F showed a horseshoe-shaped ring of variable residues around the receptorbinding pocket (Fig. 4) . Most C′-C loop interactions of IL-17RA are formed with residues that differ between IL-17A and IL-17F, whereas interactions between the amino-terminal region and F-G loop of IL-17RA D2 involve mainly conserved residues. We have reported here that the extracellular region of IL-17RA can also bind to the IL-17RB-IL-25 complex, and it has been shown that IL-17RD can interact with IL-17RA to mediate IL-17A signaling 26 . Given this association of IL-17RA with diverse IL-17 family members, we speculate that IL-17RA may act as a shared receptor analogous to those used in class I cytokine receptor complexes 27 . To investigate this possibility, we mapped onto the IL-17F surface the residues conserved among all members of the IL-17 family. In our analysis of the location of these residues in the IL-17RA-IL-17F complex, it seemed plausible that IL-17RA contacts these conserved residues with the aminoterminal region of D1 and the F-G loop of D2 (Fig. 4c) . In contrast, IL-17RA may modulate specificity for each cytokine by contacting nonconserved cytokine residues with the C-C′ loop (Fig. 4c) . Thus, IL-17RA seems to use a strategy of cross-reactivity based on a subset of conserved contacts, among a background of distinct contacts, with several different IL-17 cytokines. This is similar to the strategy used by the shared p75 receptor for the recognition of different neuro-trophin ligands 28 and is in contrast to the mechanism used for cross-reactivity by, for example, gp130 and the common γ-chain, which form largely disparate molecular interactions with different four-helix cytokines 27 .
Receptor-binding modes of cysteine-knot growth factors
Several crystal structures have been reported for complexes of receptor and cysteine-knot growth factor ligand, such as NGF [28] [29] [30] , vascular endothelial growth factor 31 , glial cell-derived neurotrophic factor family members 32 and others; these structures serve as instructive comparisons for the mode of ligand engagement mediated by IL-17RA (Fig. 5) . In the complex of NGF bound to the p75 neurotrophin receptor (p75NTR; a member of the death receptor family) 28, 30 , the receptor bears no structural similarity to IL-17RA; however, like IL-17RA, p75NTR engages NGF in a concave groove at the ligand dimer interface (Fig. 5b) . In the complex of the receptor TrkA with NGF 29, 33 , an immunoglobulin domain in TrkA, which is structurally related to the FnIII domains of IL-17RA, is used for ligand binding. However, the immunoglobulin domain of TrkA binds 'end-on' to a flat face in the 'saddle' of NGF formed by the NGF β-sheets; thus, the mode of binding is distinct (Fig. 5c) . Notably, A r t i c l e s the NGF-p75NTR complex has been reported as complexes with stoichiometries of 1:2 and 2:2 that may represent partial and complete forms of a homodimeric p75 signaling complex, respectively 28, 30 . However, in that case, homodimeric NGF ligand engages two identical p75 molecules and thus does not require a structural mechanism for the symmetric dimeric ligand to form heterodimers with two different receptors.
DISCUSSION
Cytokines of the IL-17 family are central mediators of chronic inflammatory and autoimmune conditions. Here we have reported the crystal structure of IL-17RA bound to IL-17F, which demonstrated both the receptor-binding interface and a potential mechanism by which the IL-17 family of homodimeric cytokines can coordinate two different receptors. Our structure showed one IL-17RA bound to the dimeric IL-17F cytokine, leaving the second potential receptorbinding interface free to engage a second receptor. Biochemical studies demonstrated that the heteromeric complex can be reconstituted in vitro and that the binding of the first receptor modulates the affinity of the second.
Although we have shown here that IL-17F forms heterodimeric signaling complexes with IL-17RA as a shared receptor, the possibility remains that, in principle, homodimeric receptor complexes could form in certain conditions 34, 35 . The differences in receptor affinities demonstrated by our binding data suggest that in conditions in which one type of receptor has high overexpression relative to the expression of another receptor, homodimeric signaling pairs could be formed. In this manner, cells may be able to 'tune' their responsiveness to IL-17 through heterodimeric versus homodimeric receptor complexes by a mass action-based mechanism based on modulations in relative receptor expression, as has been shown for the IL-4 and IL-13 system 36 . However, the generality of homodimeric complexes in vivo is debatable, given that cells from IL-17RA-deficient or IL-17RC-deficient mice are not responsive to IL-17A or IL-17F 9, 10 . Experiments based on fluorescence resonance energy transfer have established that IL-17RA chains exist as preformed dimers on the surface of cells 20 . The addition of cytokine causes a decrease in the efficiency of fluorescence resonance energy transfer, which suggests that the IL-17RA chains either undergo a conformational change that separates the intracellular domains or dissociate after binding. Overexpression of both IL-17RA and IL-17RC in the absence of cytokine is not sufficient to induce signaling, consistent with the idea that the cytokine elicits a change necessary for signaling 9 . Given that both IL-17RA and IL-17RC are required for signaling, it seems plausible that cytokine binding imposes the necessary receptor pairing.
The wide range of affinities between IL-17 receptors and cytokines further exacerbates this need to modulate receptor pairing. Our data indicate that pairing may be dictated by an interaction between the membrane-proximal (D2) domains of the receptors. For 'like' receptors, this may represent a repulsive force in the bound conformation that decreases the affinity for the second 'like' receptor. It has been reported that the mouse IL-17RA D2 actually mediates homotypic interactions 14 . We have not observed any dimer formation with our extracellular IL-17RA protein (data not shown), despite a high degree of conservation between the extracellular regions of mouse and human IL-17RA. As the SEF-IL-17R domains in the intracellular region of IL-17 receptors and the signaling adaptor Act1 are predicted to form dimers 3 , it seems plausible that the intracellular domains may mediate the preassembly of receptor chains, whereas cytokine binding imposes the correct receptor pairing for signaling.
IL-17RA is essential for IL-17A, IL-17F and IL-25 signaling 9,23 . IL-17RA has also been linked to IL-17RD signaling, although the ligand for this interaction remains unknown 26 . Given this emerging trend, along with our observation that IL-17RA contact residues in binding interfaces of site 1 and site 3 are somewhat conserved among members of the IL-17 cytokine family, we propose that IL-17RA may act as a shared receptor for the IL-17 family. Shared receptors such as gp130 and the common γ-chain are the hallmark of many cytokine-receptor signaling complexes 27 . These common receptors bind to an array of multimeric receptor-cytokine complexes, often in a manner mediated by their affinity for the cytokine-bound α-receptor complex rather than a direct binding affinity for the cytokine itself. IL-17RA may represent the newest member of the shared receptor family, serving in effect as a 'common γ-chain' of the IL-17R family and adding a new twist to the paradigm in which the shared receptor-binding site uses conserved 'anchor points' to engage variant ligands.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
Accession codes. UCSD-Nature Signaling Gateway (http://www. signaling-gateway.org): A001253; Protein Data Bank: coordinates and structure factors, 3JVF.
ONLINE METHODS
Protein expression and purification. The native signal peptide and extracellular region of human IL-17RA (residues 1-286) was cloned into the BacMam expression vector pVLAD6 (ref. 37) . Recombinant protein was transiently expressed at 37 °C in suspended 293 GnTI-cells grown in Pro293 media (Lonza) supplemented with 1% (vol/vol) FCS and 10 mM sodium butyrate. Full length IL-17F with a carboxy-terminal six-histidine tag was cloned into the pAcGP67-A expression vector (BD Biosciences) and protein was secreted by High Five insect cells grown at 27 °C in Insect Xpress medium (Lonza). Supernatants containing IL-17RA and IL-17F protein were mixed and concentrated before nickel-affinity purification. IL-17RA protein was deglycosylated by treatment with endoglycosidase H, and the IL-17RA and IL-17F purification tags were cleaved with 3C protease and carboxypeptidase A (Sigma-Aldrich). Protein complexes were subjected to reductive lysine methylation with dimethylamine-borane complex and formaldehyde as described 38 . The IL-17RA-IL-17F complex was further purified with a Superdex 200 size-exclusion column (GE Healthcare) equilibrated in 10 mM HEPES, pH 7.4, and 150 mM NaCl. Fractions containing the IL-17RA-IL-17F complex were concentrated to ~15 mg/ml for crystallization trials.
Selenomethionine-labeled IL-17RA protein was prepared as described 39 with the following modifications. Untransfected adherent 293 GnTI-cells were cultivated in FBS-supplemented DMEM media (Invitrogen). After a single wash in PBS, the media was replaced with methionine-and cysteinefree DMEM (Invitrogen) supplemented with l-cysteine (40 mg/l), seleniuml-methionine (45 mg/l), 2% (vol/vol) FBS, l-glutamate, sodium pyruvate, IL-17RA BacMam virus and 10 mM sodium butyrate. Expression was allowed to proceed for 72 h. IL-17RA-selenomethionine protein supernatants were mixed with IL-17F and purified as described above.
For binding experiments, proteins were expressed and purified essentially as described above. The extracellular domain of IL-17RA, IL-17RB and IL-17RCs were expressed by 293s GnTI-cells with and without a carboxy-terminal BirA ligase tag. IL-17RC was expressed with an additional carboxy-terminal Fc tag that was cleaved by 3C protease before size-exclusion chromatography. IL-17A, IL-17F and IL-25 were expressed by High Five cells with carboxy-terminal six-histidine tags. Proteins were biotinylated enymatically with BirA ligase and were purified by size-exclusion chromatography.
Crystallization and X-ray data collection. IL-17RA-IL-17F complexes were initially grown by hanging-drop vapor diffusion in 10% (vol/vol) PEG 6000 and 0.1 M bicine, pH 9.0. Optimized native and selenomethionine protein complex crystals were grown in PEG 6000 (4-14%) and 0.1 M 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid buffer, pH 9.1-9.3, with 20 mM CaCl 2 or 10 mM CaCl 2 and 1.5% (wt/vol) trimethylamine N-oxide dihydrate added directly to the protein-precipitant drop. Heavy-metal derivatives were prepared by soaking of the crystals for 6 h in 'well solution' supplemented with 0.5 mM K 2 PtCl 4 and 2% (vol/vol) ethylene glycol. Crystals were 'cryoprotected' before data collection in the 'well solution' plus 20-25% (vol/vol) ethylene glycol and were cooled to 100 K. The crystals belonged to the space group P4 1 2 1 2 and had unit cell dimensions of ~171 Å, 171 Å and 83 Å. The initial native data set was collected at the Stanford Synchrotron Radiation Lightsource beamline 9-2. The platinum-derivative and selenomethionine data sets were collected at the Stanford Synchrotron Radiation Lightsource beamline 11-1. The native data set of higher resolution was collected at the Advanced Photon Source beamline ID-23D. All data were indexed and integrated with the program Mosflm 40 and were scaled with SCALA from the CCP4 suite 41 . The diffraction is anisotropic and the initial native data set was also subjected to ellipsoidal truncation and anisotropic scaling with the diffraction anisotropy server 42 , which rendered a data set scaled to 3.4 Å, 3.4 Å and 3.9 Å.
Structure determination and refinement. A molecular-replacement solution for a single IL-17F homodimer was determined with the program Phaser 43 using the published 2.85-Å IL-17F structure as a model (Protein Data Bank accession code, 1JPY) 7 . The initial maps showed additional density on one side of the IL-17F dimer, which indicated the binding site for IL-17RA. Phases were calculated with a K 2 PtCl 4 derivative by single isomorphous replacement with anomalous scattering in the program Sharp 44 . Density-modified maps were calculated with the assumption of 71% solvent and inclusion of the partial model from the IL-17F molecular replacement for 10 of 20 rounds. A partial model of the IL-17RA main chain was built manually into this map with the program Coot 45 .
The position of the IL-17RA methionine residues was calculated by a fast Fourier transform algorithm to generate an anomalous difference map with the program FFT in the CCP4 suite. As the selenomethionine data set was not isomorphous with the native data set and the signal was too weak to locate the sites by single-anomalous-difference phasing methods, the partially built model was used as a molecular-replacement model for the selenomethionine data set and the calculated phases were used to find the selenium peaks. Three of a potential six selenomethionine residues were located, corresponding to Met159, Met166 and Met218 of IL-17RA. These methionine positions, in addition to the predicted asparagine-linked glycosylation sites and disulfide bonds, were used to register the polypeptide in the density and complete building of the initial IL-17RA model. The program Phenix 46 was used for iterative rounds of coordinate and B-factor refinement, intersected with manual model building in Coot. Initial rounds of model building used B-factor-sharpened σ A -weighted phased-combined maps calculated by the program CNS 47 . The final model was refined to 3.3 Å with R factor and R free values of 22.9% and 25.6%, respectively. There is one IL-17RA-IL-17F complex in the asymmetric unit. The model includes a dimethyl lysine at position 43 of the IL-17RA chain, five single N-acetylglucosamine sites on the IL-17RA chain, one site with two N-acetylglucosamine residues on IL-17F chain B and a calcium ion. The programs PROCHECK 48 and WHAT_CHECK 49 were used to assess the geometry of the final model. The CCP4 suite programs Contact and Areaimol were used to determined the interface contacts and buried surface area respectively. All structural figures were generated with the program Pymol 50 .
Affinity measurements. Binding affinities were calculated by SPR on a Biacore T100 (GE Healthcare). IL-17 receptors with carboxy-terminal biotinylation were coupled to immobilized streptavidin on either an SA or CM4 sensor chip (GE Healthcare). An irrelevant biotinylated protein was captured at immobilization densities equivalent to those of to control flow cells. For measurement of the second receptor-binding interaction, the cytokine was first captured by the immobilized receptor, then the second receptor was injected. Low coupling densities (200-400 RU) and excess cytokine concentrations were used to optimize the number of cytokine homodimers bound to a single receptor. The surface was regenerated with 3 M MgCl 2 between each cycle. For kinetic experiments, a flow rate of 50 µl/min was used. Data were analyzed with Biacore T100 evaluation software, version 2.0 (GE Healthcare).
